On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for adults with relapsed or refractory myeloma who have received at least one prior therapy. The CHMP is the European Medicines Agency’s (EMA) committee responsible for…
Myeloma Patients Europe has joined 14 other patient organisations members of the European Union Health Technology Assessment (EUHTA) stakeholder network to issue a joint statement on the publication of the first Joint Clinical Assessment (JCA) under the EU Health Technology Assessment Regulation (EUHTAR). The statement was coordinated by the European Patients Forum (EPF) and welcomes…
Myeloma Patients Europe (MPE) is proud to announce the launch of the Care Connect Programme, a new initiative dedicated to strengthening support for carers of people living with myeloma and AL amyloidosis across Europe. Carers play a vital role in the lives of patients, providing emotional support, practical assistance, care coordination, and advocacy throughout the myeloma pathway. However, feedback from MPE member organisations has…
MPE at EHA 2026: Stockholm in review EHA 2026 brought thousands of researchers, clinicians and patient advocates together in Stockholm for four days of cutting-edge science, discussion and connection. For the MPE team, it was a week of in-depth learning and valuable exchanges with stakeholders. What we did Across the congress we attended myeloma scientific…
On 8 June 2026, the European Commission approved the subcutaneous (under the skin) formulation of isatuximab (Sarclisa®) for use in all myeloma indications currently approved for the intravenous (IV) formulation of isatuximab. The newly approved subcutaneous formulation can be administered as a subcutaneous injection or using the CirCLIQ® on-body injector. This makes it the first…
The European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, will take place from 11–14 June in Stockholm, Sweden. The congress will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma and AL amyloidosis. Myeloma Patients Europe (MPE) will be attending EHA to keep…
To mark World Blood Cancer Day on 28 May, we are highlighting the important work of our Polish member, the Carita Foundation and how they have collaborated with us to raise awareness of important issues with Polish policymakers. The Carita Foundation has today participated in a meeting of the Parliamentary Working Group on Oncology in the Polish Parliament. This meeting…
